Cytosorbents Corporation (CTSO)

NASDAQ: CTSO · IEX Real-Time Price · USD
3.40
+0.09 (2.72%)
At close: Jun 8, 2023, 3:59 PM
3.38
-0.02 (-0.59%)
After-hours: Jun 8, 2023, 7:47 PM EDT
2.72%
Market Cap 149.44M
Revenue (ttm) 35.45M
Net Income (ttm) -31.17M
Shares Out 43.95M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE 106.38
Dividend n/a
Ex-Dividend Date n/a
Volume 65,224
Open 3.38
Previous Close 3.31
Day's Range 3.36 - 3.50
52-Week Range 1.03 - 4.59
Beta 0.75
Analysts Strong Buy
Price Target 5.50 (+61.77%)
Earnings Date Aug 1, 2023

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harves... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1997
Employees 198
Stock Exchange NASDAQ
Ticker Symbol CTSO
Full Company Profile

Financial Performance

In 2022, CytoSorbents's revenue was $34.69 million, a decrease of -19.64% compared to the previous year's $43.17 million. Losses were -$32.81 million, 33.6% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for CTSO stock is "Strong Buy" and the 12-month stock price forecast is $5.5.

Price Target
$5.5
(61.77% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

CytoSorbents Reports First Quarter 2023 Results

Pivotal U.S. and Canada STAR-T Trial enrollment enters the last third of the study. Strong customer demand from Q4 2022 continued into Q1 2023, with current expectation of overall sales growth in 2023...

1 month ago - GlobeNewsWire

CytoSorbents to Report First Quarter 2023 Operating and Financial Results

MONMOUTH JUNCTION, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac sur...

1 month ago - GlobeNewsWire

CytoSorbents Announces Board Chairman Al W. Kraus To Retire

PRINCETON, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi...

1 month ago - GlobeNewsWire
}

Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation

PRINCETON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi...

2 months ago - GlobeNewsWire

CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)

PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery us...

2 months ago - GlobeNewsWire

CytoSorbents Comments on Bank Exposure and Diversified Cash Position

PRINCETON, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi...

3 months ago - GlobeNewsWire

CytoSorbents Reports Fourth Quarter and Full Year 2022 Results

Pivotal U.S. and Canada STAR-T Trial enrollment passes halfway mark. Positive sales momentum from Q4 2022 continues in Q1 2023 to date, with expectation of sales growth in 2023

3 months ago - GlobeNewsWire

New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time

PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi...

3 months ago - GlobeNewsWire
}

CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference

PRINCETON , N.J., Feb. 27, 2023 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using ...

3 months ago - PRNewsWire

CytoSorbents to Report Fiscal 2022 Operating and Financial Results

MONMOUTH JUNCTION, N.J. , Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...

3 months ago - PRNewsWire

CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

Cumulative CytoSorb treatments surpassed 195,000. Q4 2022 product sales rebounded from Q3 2022 low.

4 months ago - PRNewsWire

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

PRINCETON, N.J. , Jan. 23, 2023 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using ...

4 months ago - PRNewsWire

CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

Dr. Irina Kulinets, seasoned U.S. and international medical device regulatory expert, joins CytoSorbents' executive management team to lead FDA marketing approval of DrugSorb®-ATR and other global reg...

5 months ago - PRNewsWire
}

CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement

Non-dilutive debt capital at market favorable terms strengthens the balance sheet and provides additional working capital to fund key clinical and commercial initiatives PRINCETON, N.J. , Dec. 29, 202...

5 months ago - PRNewsWire

CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications

PRINCETON, N.J. , Dec. 21, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...

6 months ago - PRNewsWire

CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled

PRINCETON, N.J. , Nov. 14, 2022  /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using...

7 months ago - PRNewsWire

CytoSorbents Reports Third Quarter 2022 Financial and Operational Results

CytoSorbents expects to achieve first milestone of the U.S. pivotal STAR-T Trial this month PRINCETON, N.J. , Nov. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the trea...

7 months ago - PRNewsWire

'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals

90-day survival was 74% overall, with early intervention with ECMO and CytoSorb associated with improved survival, and shorter duration on ECMO, mechanical ventilation, and ICU stay compared to late i...

7 months ago - PRNewsWire

National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma

Goal is to advance new combined blood purification technologies to treat Gram negative sepsis – a deadly global killer PRINCETON, N.J. , Oct. 31, 2022 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ...

7 months ago - PRNewsWire

CytoSorbents to Report Third Quarter 2022 Operating and Financial Results

PRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...

8 months ago - PRNewsWire

CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

PRINCETON, N.J. , Oct. 12, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...

8 months ago - PRNewsWire

CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch

PRINCETON, N.J., Oct. 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo...

8 months ago - PRNewsWire

CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma

PRINCETON, N.J. , Oct. 6, 2022 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army Me...

8 months ago - PRNewsWire

CytoSorbents to Present at the Dawson James Securities 2022 Small Cap Growth Conference

PRINCETON, N.J. , Oct. 4, 2022 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using b...

8 months ago - PRNewsWire

CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey

CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® now cleared for manufacturing from this site PRINCETON, N.J. , Sept. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatm...

9 months ago - PRNewsWire